Spelling suggestions: "subject:"technology commercialization""
31 |
Dresdner Transferbrief05 April 2013 (has links) (PDF)
Thema der Ausgabe 3(2011): Information und Kommunikation – Perspektiven und Konzepte
Für höchste Ansprüche: Software made in Saxony S. 4, 7, 9, 13
High-Tech-Gründer auf Erfolgskurs S. 5, 6, 8, 18
Vernetzt agieren ... S. 15, 16, 17
Innovativ, effektiv und serviceorientiert S. 10, 11, 12, 14, 19
|
32 |
Dresdner Transferbrief05 April 2013 (has links) (PDF)
Thema der Ausgabe 1(2012): Produktionsoptimierung – fit für die Zukunft
Effektiv und optimiert: Produkte und Verfahren S. 6, 7, 8, 12, 19
Vernetzt agieren und nachhaltig wirtschaften S. 4, 5, 10, 13, 14/15
Neue Konzepte für Fertigung und Logistik S. 9, 11, 16, 18
Auf dem Weg nach Europa S. 17
|
33 |
Dresdner Transferbrief05 April 2013 (has links) (PDF)
Thema der Ausgabe 2(2012): Energiespeicherung – Herausforderung der Energiewende
Materialforschung schafft innovative Basis S. 6, 7, 13, 14, 15
Stromspeicher – mehr als Elektromobilität S. 4/5, 8, 9, 21, 25
Kompetenzen vernetzen – regional bis weltweit S. 3, 16, 17, 18/19, 23, 24, 26
Wärmespeicher – raus aus dem Schattendasein S. 10, 11, 12, 22
|
34 |
Dresdner Transferbrief15 October 2014 (has links) (PDF)
Thema der Ausgabe 3(2014): Energiespeicherung
Innovationen für die Energiewende S. 7, 16
Die Brennstoffzelle auf dem Weg zur Marktreife S. 10, 18
Pfiffig netzwerken für unsere Zukunft S. 9, 12
|
35 |
Dresdner Transferbrief05 April 2013 (has links) (PDF)
Thema der Ausgabe 2(2003): Medizintechnik
Innovative Sensoren für die Atemgasanalyse S. 7, 12
Neue Wege in der Diagnostik S. 6, 9, 13, 14
Sensitive Gele für die Prophylaxe S. 8
Sprache im Dienst der Medizin S. 10
Technologien mit Zukunft: biokompatible Schichten S. 17
|
36 |
Dresdner Transferbrief04 February 2014 (has links) (PDF)
Thema der Ausgabe 1(2014): Innovation am Bau
Bauen in neuen Dimensionen S. 4/5
Innovative Werkstoffe für effiziente Bauweise S. 8
Auf neuen Pfaden unterwegs S. 14/15
|
37 |
Dresdner Transferbrief20 May 2014 (has links) (PDF)
Thema der Ausgabe 2(2014): Industrie 4.0
Neue Konzepte für die Produktion von Morgen S. 4/5
Die Fabrik der Zukunft erreicht die KMUs S. 16/17
Kundenorientiert und effizient fertigen... S. 24/25
|
38 |
Dresdner Transferbrief05 March 2015 (has links) (PDF)
Thema der Ausgabe 1(2015): Usability und User Experience
Das Forschungsinformationssystem (FIS) an der TU Dresden
Mit PUMa aud dem Sprung S. 5
OPAL: Aber bitte recht benutzerfreundlich! S. 6/7
In die digitale Gründerwerkstatt geschaut ... S. 13
|
39 |
Dresdner Transferbrief05 April 2013 (has links)
No description available.
|
40 |
A determination of the key factors and characteristics that SME-scale commercial biomedical ventures require to succeed in the South African environmentSayer, Jeremy Ryan 03 1900 (has links)
The potential for private sector healthcare business in Africa has been forecasted to reach $35 billion by 2016, with South Africa being regarded as the most industrially advanced country on the continent. South Africa’s entry to modern biotechnology is fairly recent, though, with companies in the private sector still in a developmental phase, and most having limited bioproduct ranges.
While considerable research has been conducted in the past to attempt to define the biotechnology environment of South Africa, as yet, a concise overview is lacking. In particular, a synopsis of the biomedical or commercial health technology environment has not been forthcoming for entrepreneurs to refer to as a ‘roadmap’. The purpose of this study was to perform a comprehensive study on the attributes that should be met for a successful, sustainable health technology venture (HTV) to be started in South Africa; while identifying the opportunities and threats that have existed in the South African market; thereby, affecting their success and sustainability to date.
In this study, two phases of research were conducted. The first was a small-sampled mixed-methods (both qualitative and quantitative) study involving 21 medical devices, biogenerics, diagnostics, and contract services companies. The second was a quantitative study, involving 107 vaccines, biogenerics, therapeutics, nutraceuticals, reagents, diagnostics, medical devices, biotools, contract services and public services companies. Inferential statistical tests were conducted on the data, including Pearson’s Chi-Square, ANOVA, bivariate correlation, linear regression, logistic regression and multinomial logistic regression.
From the study, the overall proportion of business sustainability for HTVs was found to be 66.7%, and at least 30% were unsustainable (or not yet at a level of sustainability). Variations were observed in the overall rate of sustainability for companies, based on their core functional classification, location, production type, size and start-up or R&D spending. By converting the observed frequencies of activity level, as an indication of sustainability, into a probability, it was possible to observe the company type that was most, and least likely to succeed in South Africa. Based on the statistical observations in this study, the HTV type most likely to succeed in South Africa, with a 63.7% probability of reaching sustainability, is a ‘vaccines’, ‘biotools’ or ‘public services’ company from Johannesburg with at least 20 employees; that has developed its goods or services internally, but manufactured externally and spent between R20 million–and–R30 million on its R&D or start-up. Conversely, least likely to succeed (3.2% probability) is a nutraceutical company from Cape Town with between six and 20 employees, that has developed and produced internally, and which has spent between R1 million–and–R10million on its start-up. / Life and Consumer Sciences / M. Sc. (Life Sciences)
|
Page generated in 0.1499 seconds